Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The company appointed a new director and an analyst reiterated his position on the stock.
Keros Therapeutics (KROS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Keros Therapeutics, Inc. (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 94.9% in Keros Therapeutics, Inc. (KROS). While the effectiveness of this highly sought-after metric is questionable,...
Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 96.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...
A sympathetic reaction to a competitor's drug helped push the clinical-stage pharmaceutical company's shares higher.
KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring...
LEXINGTON, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...